Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RYTM

+ Watchlist+ Portfolio

Rhythm Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$119.04
52-Week Range
$74.50 – $122.20
Market Cap
$8.10B
P/E (TTM)
—
EPS (TTM)
-2.85
Dividend Yield
0.00%
Advanced Metrics
Price/Book
92.04
PEG Ratio
—
Return on Equity
-77.96%
Return on Assets
-24.64%
Gross Margin
88.23%
Operating Margin
-66.70%
Profit Margin
-69.03%
Current Ratio
2.78
Debt/Equity
0.53
Total Debt
$106.18M
Free Cash Flow
$-17.76M
Revenue Growth
79.60%
Earnings Growth
—
Enterprise Value
$8.00B

Market Snapshot

About

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. The company markets setmelanotide, an FDA-approved melanocortin-4 receptor agonist for treating rare diseases caused by impaired MC4R pathway signaling. Rhythm is advancing a pipeline of peptide therapeutics targeting genetic obesity and related metabolic disorders.